LLY vs NVO

• LLYBuy more39%

  Eli Lilly's report on Oct 29 beat profit forecasts by 39%, and its sales grew 46% over the past year.

• NVOSell some

  Novo Nordisk still faces obesity share risk and weak analyst support, so we wouldn’t buy more and would sell some on a bounce.

Percent return

• LLY+46.30%
• NVO−12.23%

1M6MYTD1Y5YMax

Nov 11, 2025 to Nov 11, 2026

Where they differ

LLY leads on 4 of 6

LLYNVO

• Company size: LLY $1.08T, NVO $135B.
  $1.08TbiggerCompany size$135B
• Sales growth, 1 yr: LLY +46%, NVO +5.7%. LLY is ahead.
  +46%Sales growth, 1 yr+5.7%
• Price for $1 of next year's profit: LLY $29, NVO $12. NVO is ahead.
  $29Price for $1 of next year's profitcheaper$12
• Profit per $1 of sales: LLY 51¢, NVO 51¢.
  51¢Profit per $1 of sales51¢
• Cash minus debt: LLY −$43.9B, NVO −$88.1B. LLY is ahead.
  −$43.9BCash minus debt−$88.1B
• Price change, 1 yr: LLY +46%, NVO −12%. LLY is ahead. S&P 500 +12%.
  +46%Price change, 1 yr−12%
• How much the price swings: LLY 32%, NVO 36%. LLY is ahead.
  32%steadierHow much the price swings36%

Measure	LLYEli Lilly	NVONovo Nordisk A/S
Price and returns
Price	$1,437.76	$41.10
Today	+0.38%	Best in this row: +0.98%
1 month	Best in this row: +21.88%	+6.34%
3 months	Best in this row: +18.50%	−11.75%
This year	Best in this row: +34.39%	−15.21%
1 year	Best in this row: +46.30%	−12.23%
5 years	Best in this row: +472.68%	−18.74%
From 52-week high	0.0%	−32.5%
How much it swings (90 days)	Best in this row: 32%	36%
Valuation
Market value	$1.08T	$135B
Price vs last year's earnings	42.9×	Best in this row: 10.2×
Price vs next year's expected earnings	28.9×	Best in this row: 12.0×
Price vs earnings, adjusted for growth	0.95×	–
Price to sales	13.9×	Best in this row: 3.5×
Price vs cash it brings in	61.3×	Best in this row: 16.6×
Company value vs operating profit	26.9×	Best in this row: 6.9×
Price vs earnings, against its own past (0 = cheapest)	96	–
Growth
Revenue growth, 1 year	Best in this row: +45.5%	+5.7%
Revenue growth a year, last 3 years	Best in this row: +31.7%	+20.4%
Earnings per share growth, last year	Best in this row: +130.0%	+10.7%
Earnings per share growth expected next year	Best in this row: +41.5%	−1.4%
Profitability
Kept from sales after making the product	Best in this row: 83.6%	83.3%
Kept as operating profit	Best in this row: 51.3%	50.8%
Kept as final profit	31.9%	Best in this row: 33.9%
Kept as spare cash	Best in this row: 22.7%	21.5%
Profit on shareholders' money	Best in this row: 86.0%	58.4%
Profit on all money put in	Best in this row: 42.7%	42.6%
Balance sheet
Net cash (cash minus debt)	Best in this row: −$43.9B	−$88.1B
Debt for each $1 of shareholders' money	1.23×	Best in this row: 0.62×
Short-term assets per $1 of bills due	Best in this row: 1.39×	0.84×
Dividend yield	0.51%	Best in this row: 3.18%
Share of profit paid as dividends	Best in this row: 22%	34%
Our readPro
Our call	Buy more	Sell some
Why	Eli Lilly's report on Oct 29 beat profit forecasts by 39%, and its sales grew 46% over the past year.	Novo Nordisk still faces obesity share risk and weak analyst support, so we wouldn’t buy more and would sell some on a bounce.
Where the price sits	in the full report	in the full report
Our overall score (out of 100)	Best in this row: 77	55
Our value score	41	Best in this row: 78
Our growth score	Best in this row: 97	42
Our quality score	Best in this row: 87	83
Our price trend score	Best in this row: 71	33
Earnings and analysts
Analyst consensus	Buy	Hold
To average analyst target	Best in this row: +5.1%	+4.7%
Average analyst target	$1,511.30	$43.04
Analysts rating it a buy	Best in this row: 84%	21%
Buy ratings added, 3 months	Best in this row: +2	0
Analysts covering	24	4

LLY: our only Buy more, with faster sales growth

Our pick of these: Eli Lilly

Buy more90/100

Sales growth +45.5% vs +5.7%

LLY +45.5%, NVO +5.7%.

LLY+45.5%

NVO+5.7%

Forward P/E per point of sales growth 0.63 vs 2.10

LLY 0.63, NVO 2.10.

LLY0.63

NVO2.10

1-year return +46.3% vs −12.2%, S&P 500 +12.4%

LLY +46.3%, NVO −12.2%.

LLY+46.3%

NVO−12.2%

• 2ndNVOSell some10/100Would need our call to move up from Sell some

Prices as of yesterday, 3:59 PM ET. A view, not advice.